Young Lung Cancer Initiative shared a post on LinkedIn:
“For decades, KRAS was considered ‘undruggable.’
In this clip from our new KRAS Biomarker Education Series, thoracic oncologist Dr. Fawzi Abu Rous breaks down why and how the discovery of the G12C pocket changed everything for patients.
The full 3-part series is on our YouTube channel.
Thank you to Revolution Medicines for sponsoring. Editorial control stays with YLCI.”
Fawzi Abu Rous, Medical Oncologist at Henry Ford Health, shared Young Lung Cancer Initiative’s post, adding:
“Thank you to Leah Phillips and Young Lung Cancer Initiative for the kind invitation to discuss KRAS-mutant NSCLC.
We covered the evolving landscape of this mutation and how research has transformed KRAS from ‘undruggable’ to a targetable driver with real therapeutic options.
Grateful for the opportunity to be part of these important conversations.”
Zoldonrasib Shows Early Strength in Previously Treated KRAS G12D NSCLC
